$1.30+0.03 (+2.36%)
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer.
MAIA Biotechnology, Inc. in the Healthcare sector is trading at $1.30. Wall Street consensus targets $12.13 (2 analysts), implying a +833.5% move over the next 12 months. The stock is currently near its 52-week low of $0.87, remaining 13.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical de...
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and
A cancer drug developer has rocked Wall Street by implementing what is perhaps the most audacious crypto treasury strategy we have seen from a traditional biotech firm. MAIA Biotechnology (NYSE American: MAIA) announced on October 7 that its Board of Directors has approved allocating up to 90% of ...
The biotech is now running a Phase II expansion study to better evaluate the long-term benefits of ateganosine in third-line NSCLC.
The study will assess ateganosine in individuals who have been heavily pre-treated in third-line (3L) NSCLC.
MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab. Published first on TheFly – the ultimate s